Tag
This review explores barriers and facilitators influencing research participation among Black and Hispanic/Latino(a) individuals with cystic fibrosis (CF), highlighting systemic inequities, racialized experiences, and community-centered sol
A large retrospective study found that oral corticosteroids for ABPA in cystic fibrosis improve lung function, while adding antifungals offers no significant additional benefit in clinical outcomes.
This analysis of U.S. CF Foundation registry data reveals that inhaled antibiotics confer lung function benefits primarily in chronic Pseudomonas aeruginosa infections, but their treatment benefit has declined with CFTR modulator use. Risks
This study demonstrates that initiation of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in children and adolescents with cystic fibrosis improves continuous glucose monitoring (CGM) metrics, correlating with better clinical outcomes.
This prospective multicenter study demonstrates that cfDNA fetal risk screening accurately identifies autosomal recessive conditions in general-risk pregnancies with high specificity and improved positive predictive value compared to tradit
A large-scale retrospective study using US CFF Registry data reveals that CFTR modulator therapy reduces the hazard of death by 66% over an eight-year period, marking a significant milestone in cystic fibrosis clinical outcomes and life exp
A comprehensive study of 569 cystic fibrosis professionals identifies physicians as the group most vulnerable to burnout, emotional exhaustion, and depersonalization. The research highlights administrative burden as a primary driver and cal
An Italian multicentric study reveals that while ETI therapy significantly improves several health markers in Cystic Fibrosis patients, its impact on peak aerobic capacity is modest, emphasizing the indispensable need for structured physica
Elexacaftor-tezacaftor-ivacaftor significantly improves glucose tolerance, lowers A1c and sweat chloride levels, and demonstrates safety in cystic fibrosis patients with impaired glucose tolerance or cystic fibrosis-related diabetes over 48
